Ebola virus

Ebola virus is an infectious agent and one of the viruses that can cause haemorraghic fever, a severe infectious disease characterized by high fever and bleeding, in humans and some monkeys. The first infections with this viral genus were reported in Zaire, close to the river Ebola.

Latest Research and Reviews

  • Research | | open

    Human antibodies cross-reactive for several viruses within the Ebolavirus genus have been identified. Here the authors present the crystal structure of such a neutralizing monoclonal antibody (mAb) targeting the stalk of Bundibugyo virus glycoprotein and show that mAb binding may interfere with trimeric bundle assembly and/or the viral membrane.

    • Liam B. King
    • , Brandyn R. West
    • , Crystal L. Moyer
    • , Pavlo Gilchuk
    • , Andrew Flyak
    • , Philipp A. Ilinykh
    • , Robin Bombardi
    • , Sean Hui
    • , Kai Huang
    • , Alexander Bukreyev
    • , James E. Crowe Jr.
    •  & Erica Ollmann Saphire
  • Research | | open

    Genetic screens are important tools to identify host factors associated with viral infections. Here, Flint et al. perform a genome-wide CRISPR screen using infectious Ebola virus (EBOV) and show that the host transferase GNPTAB is required for EBOV infection and a potential target for antiviral therapies

    • Mike Flint
    • , Payel Chatterjee
    • , David L. Lin
    • , Laura K. McMullan
    • , Punya Shrivastava-Ranjan
    • , Éric Bergeron
    • , Michael K. Lo
    • , Stephen R. Welch
    • , Stuart T. Nichol
    • , Andrew W. Tai
    •  & Christina F. Spiropoulou
  • Research | | open

    Current experimental monoclonal antibodies (mAbs) for Ebola virus (EBOV) post-exposure immunotherapy are ineffective against Sudan (SUDV) or Marburg virus (MARV). Here, authors develop cocktails of mAbs that protect nonhuman primates against EBOV, SUDV, and MARV infection when given four days post infection.

    • Jennifer M. Brannan
    • , Shihua He
    • , Katie A. Howell
    • , Laura I. Prugar
    • , Wenjun Zhu
    • , Hong Vu
    • , Sergey Shulenin
    • , Shweta Kailasan
    • , Henna Raina
    • , Gary Wong
    • , Md Niaz Rahim
    • , Logan Banadyga
    • , Kevin Tierney
    • , Xuelian Zhao
    • , Yuxing Li
    • , Frederick W. Holtsberg
    • , John M. Dye
    • , Xiangguo Qiu
    •  & M. Javad Aman
  • Research |

    Near-atomic resolution cryo-electron microscopy structures of the Zaire ebolavirus nucleoprotein indicate a complex transition from the RNA-free to RNA-bound forms of the protein, and reveal the mechanism of oligomer formation and helical assembly.

    • Yukihiko Sugita
    • , Hideyuki Matsunami
    • , Yoshihiro Kawaoka
    • , Takeshi Noda
    •  & Matthias Wolf
    Nature 563, 137-140
  • Reviews |

    The virulence of viruses is a major determinant of the health burden of viral infections in humans and other species. In this article, Geoghegan and Holmes discuss how largely disparate research fields — theoretical modelling of virulence evolution and experimental dissection of genetic virulence determinants in laboratory model systems — can be bridged by considering real genomic data of viral evolution in a phylogenetic context. They describe the underlying principles of virulence evolution and how they apply to real-world viral infections and outbreaks of global importance.

    • Jemma L. Geoghegan
    •  & Edward C. Holmes
  • Research | | open

    The Ebola virus glycoprotein is a target for cross-protective antibodies. Here, Janus et al. report the crystal structure of the antigen-binding fragment of a pan-reactive antibody bound to a conserved epitope of the glycoprotein, facilitating rational design of cross-protective vaccines and therapeutics.

    • Benjamin M. Janus
    • , Nydia van Dyk
    • , Xuelian Zhao
    • , Katie A. Howell
    • , Cinque Soto
    • , M. Javad Aman
    • , Yuxing Li
    • , Thomas R. Fuerst
    •  & Gilad Ofek

News and Comment

  • Comments and Opinion |

    The recent large outbreak of Ebola virus disease (EVD) in Western Africa resulted in greatly increased accumulation of human genotypic, phenotypic and clinical data, and improved our understanding of the spectrum of clinical manifestations. As a result, the WHO disease classification of EVD underwent major revision.

    • Jens H. Kuhn
    • , Takuya Adachi
    • , Neill K. J. Adhikari
    • , Jose R. Arribas
    • , Ibrahima Elhadj Bah
    • , Daniel G. Bausch
    • , Nahid Bhadelia
    • , Matthias Borchert
    • , Arne Broch Brantsæter
    • , David M. Brett-Major
    • , Timothy H. Burgess
    • , Daniel S. Chertow
    • , Christopher G. Chute
    • , Theodore J. Cieslak
    • , Robert Colebunders
    • , Ian Crozier
    • , Richard T. Davey
    • , Hilde de Clerck
    • , Rafael Delgado
    • , Laura Evans
    • , Mosoka Fallah
    • , William A. Fischer II
    • , Tom E. Fletcher
    • , Robert A. Fowler
    • , Thomas Grünewald
    • , Andy Hall
    • , Angela Hewlett
    • , Andy I. M. Hoepelman
    • , Catherine F. Houlihan
    • , Giuseppe Ippolito
    • , Shevin T. Jacob
    • , Michael Jacobs
    • , Robert Jakob
    • , Frederique A. Jacquerioz
    • , Laurent Kaiser
    • , Andre C. Kalil
    • , Rashidatu F. Kamara
    • , Jimmy Kapetshi
    • , Hans-Dieter Klenk
    • , Gary Kobinger
    • , Mark G. Kortepeter
    • , Colleen S. Kraft
    • , Thomas Kratz
    • , Henry S. Kyobe Bosa
    • , Marta Lado
    • , François Lamontagne
    • , H. Cliff Lane
    • , Leslie Lobel
    • , Julius Lutwama
    • , G. Marshall Lyon III
    • , Moses B. F. Massaquoi
    • , Thomas A. Massaquoi
    • , Aneesh K. Mehta
    • , Vital Mondonge Makuma
    • , Srinivas Murthy
    • , Tonny Seikikongo Musoke
    • , Jean-Jacques Muyembe-Tamfum
    • , Phiona Nakyeyune
    • , Carolina Nanclares
    • , Miriam Nanyunja
    • , Justus Nsio-Mbeta
    • , Tim O’Dempsey
    • , Janusz T. Pawęska
    • , Clarence J. Peters
    • , Peter Piot
    • , Christophe Rapp
    • , Bertrand Renaud
    • , Bruce Ribner
    • , Pardis C. Sabeti
    • , John S. Schieffelin
    • , Werner Slenczka
    • , Moses J. Soka
    • , Armand Sprecher
    • , James Strong
    • , Robert Swanepoel
    • , Timothy M. Uyeki
    • , Michel van Herp
    • , Pauline Vetter
    • , David A. Wohl
    • , Timo Wolf
    • , Anja Wolz
    • , Alie H. Wurie
    •  & Zabulon Yoti
  • Comments and Opinion |

    Analysis reveals commercial tests for Ebola are too hard to come by in the current outbreak — sustain investment, urge Lieselotte Cnops, Kevin K. Ariën and colleagues.

    • Lieselotte Cnops
    • , Birgit De Smet
    • , Placide Mbala-Kingebeni
    • , Johan van Griensven
    • , Steve Ahuka-Mundeke
    •  & Kevin K. Ariën
    Nature 565, 419-421